DTIC ADA591994: Biomarkers of Renal Tumor Burden and Progression in... | |
by Defense Technical Information Center | |
Thumbnail | |
Download | |
Web page | |
Renal lesions occur commonly in people with TSC and can | |
cause significant morbidity and mortality [1]. Although | |
most solid renal lesions of TSC are benign angiomyolipoma | |
(AML), some are in fact cancerous. Moreover, rapidly | |
growing AMLs can be life threatening when abnormal blood | |
vessels rupture [2]. Based on the hypothesis that renal | |
tumor growth is associated with measurable changes in | |
urine composition and on the knowledge that angiogenesis | |
is essential for tumor expansion [3, 4], we have | |
predicted that factors associated with angiogenesis and | |
with renal injury will increase during periods of TSC- | |
associated renal tumor growth. We are testing this | |
candidate driven approach to identify factors in urine or | |
serum that reflect renal tumor burden and whose | |
concentrations change as tumors grow. This project can be | |
described in two aims. (A) Monitor the progression of TSC | |
renal disease by combining prospective data collection | |
with retrospective chart review of a large population of | |
TSC patients with respect to gender, age, patient size, | |
TSC genotype, renal lesions (e.g. lesion number, | |
appearance and growth rates) and renal function | |
parameters (e.g. blood pressure, serum chemistries, | |
urinalysis and urine chemistries). (B) Measure soluble | |
growth factors, angiogenesis factors and renal injury | |
molecules in urine and serum samples from patients with | |
TSC and evaluate these candidates as surrogate markers of | |
renal tumor burden and growth. | |
Date Published: 2018-09-17 03:30:03 | |
Identifier: DTIC_ADA591994 | |
Item Size: 11125035 | |
Language: english | |
Media Type: texts | |
# Topics | |
DTIC Archive; ; MASSACHUSETTS GENERAL... | |
# Collections | |
dticarchive | |
additional_collections | |
# Uploaded by | |
@chris85 | |
# Similar Items | |
View similar items | |
PHAROS | |